Introduction .................................................. vii
Contributors ................................................. xiii
Part I: General Strategies for Molecular Targeting
in Oncology
1. The Cell Cycle: Therapeutic Targeting of Cell Cycle
Regulatory Components and Effector Pathways in Cancer ....... 3
Chad D. Knights and Richard G. Pestell
2. mTOR: Properties and Therapeutics .......................... 33
John B. Easton and Peter J. Houghton
3. Ras/Raf/MEK Inhibitors ..................................... 55
Joseph A. Sparano
4. 17-AAG: Targeting the Molecular Chaperone Heat Shock
Protein 90 ................................................. 75
Len Neckers and Percy Ivy
5. The Cancer Epigenome: Can it be Targeted for Therapy? ...... 97
Sam Thiagalingam and Douglas V. Faller
Part II: Molecular Targeting for Specific Disease Sites
6. Molecular Targeting in Upper Gastrointestinal
Malignancies .............................................. 117
Scott Wadler
7. Molecular Targeting of Colorectal Cancer: An Idea Whose
Time Has Come ............................................. 133
Mark L. Sundermeyer, Alfonso Bellacosa, and
Neal J. Meropol
8. Molecular Targeting in Hepatocellular Carcinoma ........... 165
Jonathan D. Schwartz and Josep M. Llovet
9. Molecularly Targeted Therapy in Pancreatic Cancer ......... 211
Anupama Goel and Peter Kozuch
10. Untargeted Use of Targeted Therapy: A Dilemma in
Non-Small Cell Lung Cancer ................................ 227
Cheryl Ho, Angela M. Davies, Primo N. Lara,
O. Gautschi, P.С. Mack, Paul H. Gumerlock,
and David R. Gandara
11. Renal Cell Carcinoma: Renal Cell Cancer ................... 241
Olwen Hahn and Walter Stadler
12. Targeted Therapies for Prostate Cancer .................... 263
Elisabeth I. Heath and Michael A. Carducci
13. Molecular Targets in Ovarian Cancer and Endometrial
Cancer .................................................... 291
Nilofer S. Azad, Gisele Sarosy, and Elise C. Kohn
14. Targeted Therapy For Breast Cancer ........................ 309
Deena M. Atieh and Linda T. Vahdat
15. Melanoma .................................................. 343
Akshay Gupta and John M. Kirkwood
Part III: Classes of Drugs for Molecular Targeting
in Oncology
16. Antibody Therapy of Cancer ................................ 371
Hossein Borghaei, Liat Binyamin, Igor Astsaturov,
and Louis M. Weiner
17. Nucleic Acid Therapies for Cancer Treatment ............... 413
Dan T. Vogl and Alan M. Gewirtz
18. Engineering Oncolytic Measles Viruses for Targeted
Cancer Therapy ............................................ 431
Takafumi Nakamura and Stephen J. Russell
19. Vaccines as Targeted Cancer Therapy ....................... 447
Miguel-Angel Perales, Jedd D. Wolchok, and
Howard L. Kaufman
20. Cytokine-Based Therapy for Cancer ......................... 471
Henry B. Koon and Michael B. Atkins
21. Cyclooxygenase-2 as a Target for Cancer Prevention
and Treatment ............................................. 509
Monica Bertagnolli, Jaye L. Viner, and Ernest T. Hawk
Part IV: Specific Drugs for Molecular Targeting in Oncology
22. Imatinib Mesylate (Gleevec®) and the Emergence of
Chemotherapeutic Drug-Resistant Mutations ................. 545
Gerald V. Denis
23. Development of a Targeted Treatment for Cancer:
The Example of C225 (Cetuximab) ........................... 559
John Mendelsohn
24. VEGF Inhibition for Cancer Therapy ........................ 573
Shermini Saini and Herbert Hurwitz
25. Somatostatin Analogue Therapy ............................. 585
M.C. Champaneria, I.M. Modlin, I. Latich,
J. Bornschein, I. Drozdov, and M. Kidd
Part V: Challenges in Molecular Targeting in Oncology
26. Patient Selection for Rational Development of Novel
Anticancer Agents ......................................... 641
Grace K. Dy and Alex A. Adjei
27. Clinical Trial Design with Targeted Agents ................ 649
Sarita Dubey and Joan H. Schiller
28. How to Define Treatment Success or Failure if Tumors
Do Not Shrink: Consequences for Trial Design .............. 657
J.J.E.M. Kitzen, M.J.A. de Jonge, and J. Verweij
29. Molecular Imaging in Oncology ............................. 675
Lalitha K. Shankar, Anne Menkens, and
Daniel C. Sullivan
30. Combinations of Molecular-Targeted Therapies:
Opportunities and Challenges .............................. 693
Helen X. Chen and Janet E. Dancey
31. Preclinical Development of Molecularly Targeted
Agents in Oncology ........................................ 707
Joseph E. Tomaszewski and James H. Doroshow
Index ......................................................... 723
|
